DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Contactexpress Faqs Legends Search Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | AliX | Alizé Pharma | Alphelys | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Atlantic Bone Screen | Aureus Pharma | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | BioMedical Diagnostics | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-modeling) | BT Pharma | Carmat | Cellectis | Cellial Technologies | CellVax | CellVir | Cerenis Therapeutics | Cezanne | CliniGenetics | Covalab | Cytheris | Cytomics | Cytoo | DBV Technologies | DNA Therapeutics | Domain Therapeutics | Dynabio | EchoSens | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Exonhit | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | GenOdyssee | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | GTP Technology | Helios Biosciences | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences (AbAg) | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | LibraGen | Magnisense | Mapreg | MAT Biopharma | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MicroBioChips | MilleGen | MitoProd | Murigenetics | Mutabilis | Myosix | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NicOx | Nokad | Nosopharm | Nova Decision | Novagali | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharmaxon | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | PraXcell | Proteogenix | Protéus | Protexel | PX’Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sepal Pharma | Serial Genetics | Sisène Biotechnologies | Skuld-Tech | Synapcell | Synprosis | Tc Land Expression | Theraclion | TheraVectys | Transgene | Trophos | TxCell | UroGene | UROsphere | Urrma | Vaxon Biotech | Vectalys | VigiCell | Vivalis | XenTech | Zeta Biotech |

* CELLECTIS *


2000 - IDF
Romainville
(near Paris)
www.cellectis.com

Discovery, Therapy
(also Research, Subcontractor)
Key words: Genomic engineering, Meganuclease Recombination Systems (MRS), Proteins, DNA-repair
Mission: to research in, develop and market rational genome engineering technologies with 3 focus, manufacturing of proteins for therapeutic purposes, improvement of seed characteristics and development of treatments against single-gene disorders (myopathies, sickle-cell anaemia, etc.) and against the infections by DNA viruses (herpes, viral hepatitis, HIV, etc.)
Clients: Pharmaceutical industry, Biotechs, Agro industry, Research labs
Competitors: Applied Biosystems, 454 Life Sciences, Celera
mail@cellectis.com

Age: 10 year(s)

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Choulika (André) [co-founder, born 1965, Ph.D. virology]
Sc.Dir.-CSO: Pâques (Frédéric) [Ph.D. Sciences, Normale Sup (Ulm), ex-CNRS]
Fin.Dir.-CFO: Le Bozec (Marc) [HEC, ex-Alfact Innovation, Arthur D. Little, BioProtein (founder)]
BusDev: Sourdive (David) [co-founder, Ph.D. virology, Polytechnique, ex-CEO]
BusOff.: Dick Pollet [ex-Galapagos]
Lic.Dir.-CBO: Pollet (Dirk) [Ph.D. biochemistry (Antwerp), ex-Dircs Consultant, Galapagos, Glaxo Welcome, Innogenetics]
Comm.Dir.: Delassus (Sylvie) [Polytechnique (1983), Ph.D., ex-Institut Pasteur, Aventis]
Financers (Hist.): Kaminvest, BankInvest, AGF P.E., Odyssée, Edmond de Rothschild, Public

Turnover (M€) : 9.5 (2008), 1.2 (2006)
Total funding (M€) : 60.6
Last funding (M€) : 22.0
Focus : Genome
Position : Preclin
Company confirm : none

History
DATEMILESTONETYPETIME
2009 .10 Public offering (2nd) on Euronext : 22.0 M€ (1.914 Million new shares at 11.50 € each) PBO [9 years]
2009 .10 Acquisition of Vectocell Technology from Diatos assets (bankrupt in May 2009), to accelerate therapeutic development programs ACQ+ [9 years]
2009 .09 Set-up of Ectycell, a subsidiary specialized in stem cells from adults ORGC [9 years]
2009 .06 Launch of cGPS Custom, new kits for targeted gene integration in native cell lines, by affiliate Cellectis BioResearch MKTG [9 years]
2008 .12 Launch of PI10.3, a new research kit for producing stable cell clones using gene targeting in just 4 weeks, by affiliate Cellectis BioResearch MKTG [8 years]
2008 .11 Research : publication in Nature Magazine on a Therapeutic Meganuclease to treat a severe skin inborn disease by the CNIO, the CRG and Cellectis R&D [8 years]
2008 .09 Financing agreement by AFM (French Muscular Dystrophy Association), 8.3 M€ granted over 5 years for research on 7 genes surgery of orphan diseases RFIN [8 years]
2008 .06 Court : legal dispute on patents against Shionogi LEGAL [8 years]
2008 .05 Set-up of 2 new subsidiaries in France, Cellectis Bioresearch and Cellectis Genome Surgery ORGC [8 years]
2007 .02 Listing on Euronext Paris : 21.2 M€ PBO [7 years]
2005 .06 3rd round-financing : 5.6 M€, by BankInvest, AGF P.E., Odyssée, Edmond de Rothschild (follow-up) RFINC [5 years]
2004 .04 Company move from Paris (Institut Pasteur) to Biocitech in Romainville ORGL [4 years]
2002 .05 2nd round-financing : 8.0 M€, by BankInvest, AGF PE, Odyssée, Edmond de Rothschild RFINB [2 years]
2000 .11 1st round-financing : 3.8 M€, by Kaminvest RFINA [0 year]
2000 .06 Licensing-in of 6 lead products from Institut Pasteur (spin-off with equity) LICIN [0 year]
2000 .01 Company founded by André Choulika and David Sourdive ORGF [0 year]

Actualisation / Updating: 08-Feb-2010


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT
Pour retourner à la page d'accueil Biotech: BIENVENUE !

Haut de page :

Copyright J.H. Huber, Pharmaclient 2001-2010.

Pharmaclient, le site de la valorisation client en Pharma, est la vitrine des activités de conseil de Jean Huber: Stratégie, Communication, Relation Client en Pharma.